VELA Investment Management LLC Has $2.19 Million Stock Holdings in Icon Plc $ICLR

Posted by Brian Himes on Sep 7th, 2026

VELA Investment Management LLC boosted its position in shares of Icon Plc (NASDAQ:ICLR – Free Report) by 531.4% during the 2nd quarter, HoldingsChannel reports. The fund owned 12,590 shares of the medical research company’s stock after buying an additional 10,596 shares during the quarter. VELA Investment Management LLC’s holdings in Icon were worth $2,187,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the company. Concurrent Investment Advisors LLC bought a new stake in shares of Icon in the 2nd quarter worth approximately $6,337,000. Clifford Swan Investment Counsel LLC acquired a new stake in shares of Icon during the 2nd quarter worth approximately $236,000. Maple Rock Capital Partners Inc. increased its position in shares of Icon by 257.8% during the second quarter. Maple Rock Capital Partners Inc. now owns 1,199,600 shares of the medical research company’s stock valued at $208,383,000 after purchasing an additional 864,300 shares during the period. American Capital Management Inc. bought a new stake in shares of Icon during the second quarter valued at approximately $490,000. Finally, Firetrail Investments PTY Ltd. acquired a new position in shares of Icon in the second quarter valued at $12,021,000. Institutional investors and hedge funds own 95.61% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. DA Davidson set a $164.00 target price on Icon in a research report on Monday, June 1st. Mizuho boosted their price target on shares of Icon from $180.00 to $190.00 and gave the company an “outperform” rating in a report on Friday, June 26th. Royal Bank Of Canada upgraded shares of Icon from a “sector perform” rating to an “outperform” rating and increased their price objective for the company from $126.00 to $185.00 in a research note on Thursday, June 25th. Leerink Partners set a $145.00 price objective on shares of Icon in a report on Thursday, May 28th. Finally, William Blair upgraded shares of Icon to a “strong-buy” rating in a research report on Thursday, July 30th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $170.40.

Check Out Our Latest Stock Analysis on ICLR

Icon Stock Performance

Shares of ICLR opened at $164.85 on Monday. The company has a current ratio of 0.95, a quick ratio of 0.95 and a debt-to-equity ratio of 0.23. The stock has a market cap of $12.62 billion, a PE ratio of 38.70, a PEG ratio of 7.61 and a beta of 1.20. Icon Plc has a 1 year low of $66.57 and a 1 year high of $203.91. The stock has a 50 day simple moving average of $168.05 and a 200-day simple moving average of $135.82.

Icon (NASDAQ:ICLR – Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The medical research company reported $2.56 EPS for the quarter, beating the consensus estimate of $2.55 by $0.01. Icon had a return on equity of 8.02% and a net margin of 3.99%.The business had revenue of $2.06 billion for the quarter, compared to analyst estimates of $2 billion. During the same quarter in the previous year, the firm earned $3.26 EPS. Icon’s quarterly revenue was up 2.3% on a year-over-year basis. On average, sell-side analysts predict that Icon Plc will post 9.58 EPS for the current fiscal year.

Insider Activity at Icon

In other news, Director Anne Whitaker sold 841 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $164.29, for a total value of $138,167.89. Following the sale, the director owned 891 shares in the company, valued at approximately $146,382.39. The trade was a 48.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Eugene Mccague sold 841 shares of the company’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $164.29, for a total transaction of $138,167.89. Following the completion of the sale, the director directly owned 3,811 shares in the company, valued at approximately $626,109.19. The trade was a 18.08% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 9,531 shares of company stock valued at $1,565,764. Insiders own 44.00% of the company’s stock.

Icon Company Profile

(Free Report)

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.